Skip to main content
BMJ Case Reports logoLink to BMJ Case Reports
. 2019 Jun 16;12(6):e231267. doi: 10.1136/bcr-2019-231267

Aromatase deficiency: a rare cause of maternal virilisation and ambiguous genitalia in neonates

Mahdi Alsaleem 1, Diana E Miller 1, Lina Saadeh 1, Indrajit Majumdar 1
PMCID: PMC6577309  PMID: 31208983

Description

We describe a full term infant born to a 28-year-old mother. Pregnancy was uncomplicated except for maternal signs of virilisation: hoarseness of voice, excess facial hair and a significant nasal enlargement. Perinatal vitamins were the only medication taken by the mother during pregnancy. Family history is significant for consanguinity. In her previous two pregnancies, the mother had developed similar virilisation symptoms that resolved shortly after birth. The outcomes for these two pregnancies were healthy term male newborns with normal physical examinations. The infant was active at birth with stable vital signs and appropriate growth parameters; however, concerning physical examinations of the genitalia necessitated transfer to our tertiary centre for further evaluation. The admission examination was significant for an enlarged phallus, complete fusion of the labioscrotal folds, absence of vaginal opening and non-palpable gonads (Prader stage 3–4) as shown in figure 1. Rest of the physical examination was within normal limits, and the baby had no limb abnormalities. Laboratory investigations on admission showed cord blood oestradiol level of 2120 pg/mL (9000–34 000 pg/mL),  androstenedione was 24 840 ng/dL (nl<80 ng/dL) and dehydroepiandrosterone sulfate DHEA-S of 1420 mcg/dL (nl<360 mcg/dL). At 12 hours of life, infant’s FSH (Follicle stimulating hormone)  was 0.264 mIU/mL and LH (Luteinizing hormone) was 0.147  mIU/mL, both within normal range and total testosterone was 90 ng/dL (16–44 ng/dL). At 72 hours, infant’s 17-OHP was 24 ng/dL (nl<78) and androstenedione was 52 ng/dL (days 1–7; 20–290 ng/dL).

Figure 1.

Figure 1

Ambigious genitalia due to placental aromatase enzyme deficiency.

Maternal labs drawn 6 hours’ postpartum were notable for oestradiol of 2200 pg/mL (6137–3460 ng/dL) and testosterone concentration was 1307 ng/dL (63–309 ng/dL). On the fourth day postpartum, both maternal oestradiol and testosterone levels were 726 pg/mL and 599 ng/dL, respectively. Electrolyte concentrations were stable during the 2 weeks hospitalisation period. Chromosomal analysis resulted in 46, XX karyotype. Infant’s pelvic ultrasonography revealed the presence of a uterine structure behind the bladder (figure 2). At the follow-up appointment at 2 months of age, maternal virilisation signs and symptoms resolved. Both maternal’s and infant’s androgen and oestradiol levels improved.

Figure 2.

Figure 2

Pelvic ultrasonography image, revealing a uterine structure (between the asterisks) behind the bladder. Obtained by Mahdi Alsaleem.

In the case presented, the mother manifested with signs of antenatal androgen excess, while the 46, XX infant had virilised external genitalia at birth. Both maternal and infant’s symptoms improved significantly with time. The most likely explanation for these findings is the antenatal androgen excess associated with oestrogen deficiency from the inability to convert androgens into oestradiol in the fetus due to placental aromatase deficiency.

Aromatase deficiency was first described in Japan in 1991 in a newborn who presented with ambiguous genitalia, who later was found to have aromatase P450 gene defect.1 The incidence in neonates is unknown due to very few cases reported in the medical literature.2 The inheritance pattern is an autosomal recessive defect of the gene coding for aromatase enzyme located on chromosome 15 P21.1. Diagnosis can be missed if the genitalia abnormalities are subtle; in these cases, female patients present later in adulthood with primary amenorrhea and virilising symptoms. Both male and female patients with aromatase deficiency can present with tall stature, delayed bone age, osteoporosis and hyperglycaemia.3 4

Congenital adrenal hyperplasia (CAH) is an essential differential. The priority of management in similar cases with ambiguous genitalia is to rule out CAH to prevent the life-threatening complication of adrenal crisis that can result in hypotension and salt wasting.

Learning points.

  • Maternal history is an essential part of the clinical evaluation for an infant with ambiguous genitalia.

  • History of maternal virilisation during pregnancy should alert the clinicians to the possibility of aromatase enzyme deficiency diagnosis.

  • If aromatase enzyme deficiency is suspected, workup should include serial measurement of the androgen and oestrogen levels of both the mother and the infant.

Footnotes

Contributors: MA, DEM, LS and IM have contributed to the design, acquisition and analysis of data. All authors contributed to the drafting and revising this manuscript. MA, DEM, LS and IM approved this final version of this draft and agreed to be accountable for the article and to ensure that all questions regarding the accuracy or integrity of the article are investigated and resolved.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

Patient consent for publication: Parental/Guardian consent obtained.

References

  • 1. Shozu M, Akasofu K, Harada T, et al. A new cause of female pseudohermaphroditism: placental aromatase deficiency. J Clin Endocrinol Metab 1991;72:560–6. 10.1210/jcem-72-3-560 [DOI] [PubMed] [Google Scholar]
  • 2. Jones ME, Boon WC, McInnes K, et al. Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab 2007;3:414–21. 10.1038/ncpendmet0477 [DOI] [PubMed] [Google Scholar]
  • 3. Rochira V, Carani C. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol 2009;5:559–68. 10.1038/nrendo.2009.176 [DOI] [PubMed] [Google Scholar]
  • 4. Belgorosky A, Guercio G, Pepe C, et al. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm Res 2009;72:321–30. 10.1159/000249159 [DOI] [PubMed] [Google Scholar]

Articles from BMJ Case Reports are provided here courtesy of BMJ Publishing Group

RESOURCES